The funding comes from the Foundation Fighting Blindness' venture philanthropy arm, the Retinal Degeneration Fund.

The team is currently developing the PROX1 antibody through KAIST spinout, Cellia Inc., and hopes to begin human trials in 2028 for patients with retinitis pigmentosa and other retinal diseases ...

Keywords: novel strategy, antiviral, cytomegalovirus retinitis, letermovir, maribavir. Citation: Yao Y, Zeng Q, Sun Y, Jin E, Tang J, Cai Y, Hou J and Miao H (2025) A novel strategy for the management ...

Vision loss is also one of the major, progressive symptoms of X-linked retinitis pigmentosa (XLRP). It is caused by mutations in genes located on the X chromosome, which means the condition ...

Chitra Kannabiran, PhD, Kallam Anji Reddy Molecular Genetics Laboratory, Hyderabad Eye Research Foundation, Champalimaud Translational Centre, LV Prasad Eye Institute, Hyderabad 500 034, India ...

Ocugen Inc, a biotechnology company focused on discovering, developing, and commercializing novel gene therapies to address major blindness diseases and offer hope for patients across the globe, ...

MALVERN, Pa., June 05, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc., a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the signing of a binding term sheet to ...

Ocugen, Inc. has signed a binding term sheet to negotiate a licensing agreement for OCU400, its gene therapy for retinitis pigmentosa (RP), with a major pharmaceutical company in Korea, granting ...

Ocugen, Inc. Announces Signing Of Binding Term Sheet For The License Of OCU400 Modifier Gene Therapy For Retinitis Pigmentosa In Korea. Date. 2025-06-05 07:16:07. Share on Facebook; ...

Upfront fees and near-term development milestone payments totaling up to $11 millionSales milestones of $150 million or more in first 10 years of commercializationRoyalties equaling 25% of net ...

OCU400 is Ocugen’s novel modifier gene therapy for retinitis pigmentosa (RP). The OCU400 (AAV5-h NR2E3 ) gene therapy platform delivers the nuclear hormone receptor NR2E3 to the retina and retinal ...